Initial Hep C Data on ACH-2928 Is Encouraging
Share
Follow Us
Achillion Announces Preliminary Phase 1b Proof-of-Concept Data With ACH-2928 NS5A Inhibitor for the Treatment of Hepatitis C Achieves 3.68 Log10 Reduction in HCV RNA After Three Days of Treatment
NEW HAVEN, Conn., Dec 5, 2011 (GlobeNewswire via COMTEX) — Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported proof-of-concept data from its Phase 1b clinical trial of ACH-2928, a first-generation NS5A inhibitor, demonstrating that patients treated with ACH-2928 achieved a mean maximum 3.68 log10 reduction in HCV RNA after three-day monotherapy of 60 mg once daily. The compound also demonstrated good safety and tolerability both in healthy volunteers and in patients with chronic hepatitis C (HCV).
ACH-2928, Achillion’s first generation inhibitor of the NS5A protein, was discovered through the Company’s NS5A inhibitor program. Achillion also recently nominated a second-generation NS5A inhibitor, ACH-3102, which is currently undergoing IND-enabling studies and is expected to be advanced into clinical trials during the first half of 2012.
Continue reading this entire article:
http://www.marketwatch.com/story/achillion-announces-preliminary-phase-1b-proof-of-concept-data-with-ach-2928-ns5a-inhibitor-for-the-treatment-of-hepatitis-c-2011-12-05
